Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Radiopharmacies Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The radiopharmacies market has experienced substantial expansion in recent years. Its value is expected to increase from $10.3 billion in 2025 to $11.12 billion in 2026, progressing at a compound annual growth rate (CAGR) of 8.0%. This historical growth can be linked to the rising prevalence of cancer and chronic diseases, the increasing adoption of nuclear medicine imaging procedures, a growing demand for accurate diagnostic radiopharmaceuticals, the expansion of hospital-based nuclear medicine departments, and an enhanced regulatory focus on the safe handling of radioactive materials.
The radiopharmacies market is anticipated to experience robust expansion over the coming years. This market is projected to reach $15.26 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.2%. This expansion during the forecast period is fueled by several factors, including the rising development of targeted radionuclide therapies, increased investment in PET and SPECT imaging technologies, the broadening scope of personalized medicine applications, the growing establishment of centralized radiopharmacy networks, and the escalating demand for sophisticated radiopharmaceutical logistics and cold chain solutions. Key trends anticipated during this period encompass a surging demand for targeted radiopharmaceutical therapies in oncology, the expanding uptake of centralized radiopharmacy services for streamlined dose preparation, a heightened emphasis on radiation safety and regulatory adherence within radiopharmacies, the broadening of nuclear medicine applications in fields such as cardiology and neurology, and increased investment in advanced quality control and assurance systems for managing radiopharmaceuticals.
Get A Free Sample Report With In-Depth Market Insights:
Radiopharmacies Market Growth Catalysts And Demand Drivers
The increasing occurrence of cancer and various chronic diseases is projected to stimulate the expansion of the radiopharmacies market moving forward. Cancer and chronic diseases refer to persistent health conditions, such as cancer, diabetes, heart disease, and respiratory ailments, which demand continuous medical attention and can endure for extended periods. The rising prevalence of these conditions is linked to aging populations, as individuals naturally face an elevated risk of developing long-term illnesses like cancer, diabetes, and heart disease as they grow older. Radiopharmacies facilitate the diagnosis and treatment of cancer and chronic diseases by producing and supplying specialized radioactive drugs employed in medical imaging and targeted therapies, enabling precise detection, monitoring, and intervention for these conditions. For instance, in February 2024, the World Health Organization indicated that over 35 million new cancer cases are anticipated by 2050, representing a 77% surge from the approximately 20 million cases estimated in 2022. Consequently, the growing prevalence of cancer and chronic diseases is a key driver for the radiopharmacies market’s growth.
Radiopharmacies Market Segment Performance And Emerging Opportunities
The radiopharmacies market covered in this report is segmented –
1) By Product Type: Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals
2) By Service Type: Radiopharmaceutical Compounding, Dose Preparation, Nuclear Medicine Drug Dispensing, Quality Control And Assurance, Radiation Safety Management, Logistics And Delivery, Inventory Management, Regulatory Compliance Support, Consulting And Training Services
3) By Radioisotope Type: Technetium-Based Radiopharmaceuticals, Fluorine-Based Radiopharmaceuticals, Iodine-Based Radiopharmaceuticals, Gallium-Based Radiopharmaceuticals, Lutetium-Based Radiopharmaceuticals, Other Radioisotope Types
4) By Application: Oncology, Cardiology, Neurology, Endocrinology, Other Applications
5) By End User: Hospitals, Diagnostic Imaging Centers, Research Institutes, Specialty Clinics
Subsegments:
1) By Diagnostic Radiopharmaceuticals: Single Photon Emission Computed Tomography Radiopharmaceuticals, Positron Emission Tomography Radiopharmaceuticals, Bone Imaging Radiopharmaceuticals, Cardiac Imaging Radiopharmaceuticals, Renal Imaging Radiopharmaceuticals
2) By Therapeutic Radiopharmaceuticals: Radioiodine Therapy Radiopharmaceuticals, Radiolabeled Antibody Therapy, Peptide Receptor Radionuclide Therapy, Bone Pain Palliation Radiopharmaceuticals, Liver Cancer Therapy Radiopharmaceuticals
Radiopharmacies Market Trends Shaping Long-Term Demand
Leading firms within the radiopharmacies market are prioritizing the creation of novel strategies, including sophisticated radiopharmaceutical manufacturing sites, to boost production effectiveness and guarantee a steady provision of both diagnostic and therapeutic radiopharmaceuticals. These cutting-edge facilities are specialized hubs dedicated to producing radioactive compounds for medical imaging and treatment, characterized by high precision and safety. They contribute to maintaining consistent quality, expediting production, and ensuring a dependable flow of diagnostic and therapeutic radiopharmaceuticals. As an illustration, in October 2024, PharmaLogic Holdings Corp., a US-based manufacturing enterprise, inaugurated a modern radiopharmaceutical production plant in Los Angeles. This expansion aims to augment its capability to deliver essential imaging agents. This new site incorporates automated synthesis modules, rigorous quality control measures, and adaptable production lines, facilitating the manufacture of consistent and high-purity radiotracers. Furthermore, it supports the fabrication of PET and SPECT imaging agents, thereby decreasing human error, lessening contamination hazards, and enhancing turnaround times when contrasted with traditional laboratories.
Radiopharmacies Market Leading Companies And Competitive Benchmarking
Major companies operating in the radiopharmacies market are Cardinal Health Inc., Siemens Healthineers AG, GE HealthCare Technologies Inc., BWX Technologies Inc., Bracco Imaging S. p. A., Lantheus Holdings Inc., China Isotope & Radiation Corporation, Ion Beam Applications S. A. (IBA), Telix Pharmaceuticals Limited, Eckert & Ziegler Strahlen, PharmaLogic Holdings Corp., Shine Technologies LLC, NTP Radioisotopes SOC Ltd., NorthStar Medical Radioisotopes LLC, ITM Isotope Technologies Munich SE, ARTBIO Inc., Isotopia Molecular Imaging Ltd., AdvanCell Isotopes Pty Ltd, Futurechem Co. Ltd., Jubilant Radiopharma Pvt. Ltd., Cyclotek (Aust) Pty Ltd., Radiomedix Inc., Iso-Tex Diagnostics Inc., Nucleus RadioPharma Inc.
View The Full Radiopharmacies Market Report:
Radiopharmacies Market Top Region By Revenue And Market Share
North America was the largest region in the radiopharmacies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radiopharmacies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.
